Cover Image
市場調查報告書

破傷風 : 開發中產品分析

Tetanus - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192846
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
破傷風 : 開發中產品分析 Tetanus - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 100 Pages
簡介

所謂破傷風是破傷風菌所引起的嚴重疾病。主要的前兆·症狀有下巴肌肉的痙攣和僵直化,吞嚥障礙,腹肌僵直化,發熱,發汗,血壓·心律上升等。易罹病素質包含了燒燙傷,及外科手術造成的外傷,耳朵的感染疾病,外傷部分附近的水腫,足部潰瘍(的感染)等。主要的治療藥有抗生素和鎮靜劑,乙型阻斷劑等。

本報告提供全球各國治療破傷風所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

破傷風概要

治療藥的開發

  • 破傷風開發中產品:概要
  • 破傷風開發中產品:比較分析

各企業開發中的破傷風治療藥

大學/研究機關研究中的破傷風治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

破傷風治療藥:開發中的產品的一覽(各企業)

破傷風治療藥:研究中的產品的一覽(各大學/研究機關)

破傷風開發治療藥的企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Bharat Biotech International Limited
  • BioClonetics Immunotherapeutics, Inc.
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • 第一三共
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • Indian Immunologicals Limited
  • 化學和血清療法學會(化血研)
  • LG Life Science LTD.
  • Panacea Biotec Limited
  • Prometheon Pharma, LLC
  • Sanofi Pasteur SA
  • Serum Institute of India Limited
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

破傷風:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各投藥法
  • 各分子類型

藥物簡介

破傷風治療藥:開發暫停的產品

破傷風治療藥:開發中止的產品

破傷風相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8482IDB

Summary

Global Markets Direct's, 'Tetanus - Pipeline Review, H2 2016', provides an overview of the Tetanus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Tetanus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tetanus
  • The report reviews pipeline therapeutics for Tetanus by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Tetanus therapeutics and enlists all their major and minor projects
  • The report assesses Tetanus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Tetanus

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Tetanus
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tetanus Overview
  • Therapeutics Development
    • Pipeline Products for Tetanus - Overview
    • Pipeline Products for Tetanus - Comparative Analysis
  • Tetanus - Therapeutics under Development by Companies
  • Tetanus - Therapeutics under Investigation by Universities/Institutes
  • Tetanus - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Tetanus - Products under Development by Companies
  • Tetanus - Products under Investigation by Universities/Institutes
  • Tetanus - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Bharat Biotech International Limited
    • BioClonetics Immunotherapeutics, Inc.
    • Biological E. Limited
    • Boryung Pharmaceutical Co., Ltd.
    • Daiichi Sankyo Company, Limited
    • GlaxoSmithKline Plc
    • Green Cross Corporation
    • Indian Immunologicals Limited
    • Kaketsuken K.K.
    • LG Life Science LTD.
    • Panacea Biotec Limited
    • Prometheon Pharma, LLC
    • Sanofi Pasteur SA
    • Serum Institute of India Limited
    • Sinovac Biotech Ltd.
    • Zydus Cadila Healthcare Limited
  • Tetanus - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • diphtheria + pertussis(acellular) + tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Eupenta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-1107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-3111A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Tetanus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Tetanus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Target Tetanus Toxin for Tetanus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tetanus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Tetanus - Dormant Projects
  • Tetanus - Discontinued Products
  • Tetanus - Product Development Milestones
    • Featured News & Press Releases
      • Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta
      • Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
      • Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
      • Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age
      • Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima
      • Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine
      • Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets
      • Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency
      • Mar 13, 2008: U.S. FDA Licenses DAPTACEL Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
      • Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
      • Jun 13, 2005: U.S. FDA Licenses sanofi Pasteur's ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
      • Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine
      • Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur's ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
      • Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults.
      • May 14, 2002: Food and Drug Administration Approval of a Fifth Acellular Pertussis Vaccine for Use Among Infants and Young Children
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Tetanus, H2 2016
  • Number of Products under Development for Tetanus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Tetanus - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
  • Tetanus - Pipeline by Bharat Biotech International Limited, H2 2016
  • Tetanus - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016
  • Tetanus - Pipeline by Biological E. Limited, H2 2016
  • Tetanus - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2016
  • Tetanus - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Tetanus - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Tetanus - Pipeline by Green Cross Corporation, H2 2016
  • Tetanus - Pipeline by Indian Immunologicals Limited, H2 2016
  • Tetanus - Pipeline by Kaketsuken K.K., H2 2016
  • Tetanus - Pipeline by LG Life Science LTD., H2 2016
  • Tetanus - Pipeline by Panacea Biotec Limited, H2 2016
  • Tetanus - Pipeline by Prometheon Pharma, LLC, H2 2016
  • Tetanus - Pipeline by Sanofi Pasteur SA, H2 2016
  • Tetanus - Pipeline by Serum Institute of India Limited, H2 2016
  • Tetanus - Pipeline by Sinovac Biotech Ltd., H2 2016
  • Tetanus - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Tetanus - Dormant Projects, H2 2016
  • Tetanus - Dormant Projects (Contd..1), H2 2016
  • Tetanus - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Tetanus, H2 2016
  • Number of Products under Development for Tetanus - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top